Monthly research recap
DMT research: October 2026
What October 2026's 9 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.
Research indexed to 2026 on DMT is mostly preclinical, methodological, or theoretical rather than new controlled human trials. The strongest human signals are indirect: a systematic review reports rapid antidepressant effects for N,N-DMT and 5-MeO-DMT, and a prospective observational study of 113 veterans found large, largely stable reductions in PTSD, depression, anxiety, and suicidal ideation after ibogaine plus 5-MeO-DMT treatment in Mexico, though without a control group. Animal and analytical work supports fear-memory and plasticity effects and characterizes DMT metabolites, while several papers are hypotheses or proposals with no outcome data. The main caveats are small or uncontrolled human samples, absence of blinding, and preliminary evidence outside depression.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025). 2026 | systematic review | 52 | Mixed | Population surveys showed no consistent link between lifetime psychedelic use and psychosis and controlled trials showed minimal risk, while case reports and emergency data showed higher symptom rates, with personal or family psychiatric history and unsupervised use as apparent risk factors. |
| Title: DMT, Salvinorin A, and Stress Regulation: An Exploratory Neuropharmacological Research Proposal 2026 | theoretical | Unclear | Argues for a research framework comparing serotonergic DMT with kappa-opioid salvinorin A in stress regulation, without reporting original human experiments or treatment outcomes. | |
| Is the Prostate a Site of Endogenous DMT Synthesis? A Testable Hypothesis 2026 | theoretical | Unclear | Proposes that prostatic tissue may synthesize DMT and/or 5-MeO-DMT and outlines a staged LC-MS/MS-based experimental programme, explicitly as a testable hypothesis rather than an established explanation. | |
| Analytical characterization of novel psychoactive substances and adulterants: ortho-methyl fentanyl, N,N-dimethyltryptamine, and medetomidine 2026 | preclinical experimental | Supports | Identified and quantified DMT and its metabolites using human liver microsomes and LC-QQQ-MS, and found intranasal DMT effects in rats comparable to those reported in humans. | |
| Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network 2026 | qualitative | 4 | Mixed | Participants described trial procedures and facilitators as shaping their dosing experiences, saw dosing as the start of ongoing integration, and reported loss or frustration after study end while recommending independent peer support. |
| Ayahuasca Impairs Fear Memory Reconsolidation and Promotes Rapid Structural Plasticity in the Hippocampus and Prelimbic Cortex. 2026 | controlled animal experiment | Supports | Ayahuasca (60 mg/kg) around fear memory retrieval reduced freezing, indicating impaired fear memory reconsolidation, alongside increased dendritic spine density in hippocampal and prelimbic regions without changes in adult neurogenesis. | |
| Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review. 2026 | systematic review | 51 | Supports | Across 51 publications, N,N-DMT and 5-MeO-DMT were associated with rapid reductions in depressive symptoms and inhalable 5-MeO-DMT met its primary endpoint in a Phase 2b treatment-resistant depression trial, while evidence for other conditions remained preliminary. |
| Ibogaine and 5-MeO-DMT Treatment in Mexico: Adverse Events, Suicidal Ideation, Mental Health, and Psychological Flexibility Among United States Military Veterans 2026 | prospective observational | 113 | Supports | From baseline to 9 months, veterans showed significant reductions in PTSD, depression, anxiety, and suicidal ideation with transient, infrequent adverse events, and acute psychedelic intensity predicted greater PTSD and anxiety improvement. |
| Synthesis of 1,2,3‐Triazole Derivatives of N , N ‐Dimethyltryptamine Isolated From Mimosa tenuiflora Root Bark: Antiplasmodial Activity In Silico and In Vitro 2026 | preclinical in vitro and in silico | Supports | Semisynthetic triazole derivatives of DMT showed markedly stronger antiplasmodial activity than the parent compound (IC50 4.8 vs 288.4 µM) with higher selectivity, and more favorable in silico binding energies. |
Points of agreement
- Human evidence points to rapid symptom reduction with short-acting tryptamines, especially for depression, and observational data extend benefits to PTSD, anxiety, and suicidal ideation.
- Controlled and population-level data suggest low psychosis risk with supervised use, with risk concentrated in people with psychiatric history or unsupervised use.
- Preclinical work links DMT-containing preparations to synaptic remodeling and fear-memory effects rather than neurogenesis.
Conflicts
- Psychosis risk appears minimal in controlled settings and population surveys but higher in emergency, toxicology, and case-report data.
- Human benefit signals come largely from uncontrolled observational data, while controlled trial evidence is concentrated in depression and remains preliminary for other conditions.
Gaps
- No new randomized controlled human DMT trial results are reported; most human outcome data are observational or reviewed from earlier trials.
- Durability beyond 9 months, blinding integrity, and dose-response relationships are not established.
- Evidence in non-veteran, non-treatment-resistant populations and for conditions other than depression is preliminary.
- Several DMT papers are hypotheses or proposals with no empirical outcomes.